Qualigen Therapeutics Presents Data On QN-247 in Triple Negative Breast Cancer at the American Association for Cancer Research (AACR) Annual Meeting in Orlando, FL
18 Aprile 2023 - 1:30PM
Qualigen Therapeutics, Inc. (“Qualigen” or “the Company,” Nasdaq:
QLGN), a diversified life sciences company focused on developing
treatments for adult and pediatric cancers with potential for
Orphan Drug Designation, while also commercializing diagnostics,
today announces data from the Company’s poster presented at the
American Association for Cancer Research (AACR) Annual Meeting 2023
held April 14-19 in Orlando, FL. The Company presented in vivo
efficacy data regarding its QN-247 program, for which it is
actively seeking partners.
“These encouraging data demonstrate QN-247 may
be an effective nano-immunotherapy against triple negative breast
cancer. They are an important validation for our development
approach, and we believe they will be meaningful as we actively
seek opportunities around this compound,” said Michael Poirier,
Qualigen’s Chairman and CEO.
Highlights from QN-247 Poster:
Abstract #2708
“Nano-immunotherapy: Efficacy of
nanoconjugate QN-247 in a Triple Negative Breast Cancer (TNBC)
mouse model”
Tariq Arshad, Stephen Fait, Guy Gammon, Andrew Hertig, Mark J.
Sarno
Study authors had prepared QN-247 conjugates
that build upon the legacy of the anti-proliferative DNA aptamer
AS1411. The process developed to produce QN-247 conjugates results
in colloidally stable material that is manufacturable and scalable.
QN-247 is active in vitro against a variety of cancers including
prostate cancer and Triple Negative Breast Cancer (TNBC), and more
potent than the anti-proliferative aptamer AS1411 itself. In
addition, QN-247 is effective in vivo against a xenograft mouse
TNBC model showing highly significant reductions in tumor volumes
with no evidence of toxicity.
About QN-247
QN-247 is a nucleolin-targeted oligonucleotide
conjugate with potential indications against nucleolin expressing
malignancies such TNBC, Acute Myeloid Leukemia (AML), Glioblastoma
(GBM) and others. The company is currently seeking partners to
advance QN-247 program in TNBC and other malignancies.
About Qualigen
Therapeutics, Inc.
Qualigen Therapeutics, Inc. is a diversified
life sciences company focused on developing treatments for adult
and pediatric cancer, while also commercializing diagnostics. Our
investigational QN-302 compound is a small molecule selective
transcription inhibitor with strong binding affinity to G4s
prevalent in cancer cells; such binding could, by stabilizing the
G4s against “unwinding,” help inhibit cancer cell proliferation.
The investigational compounds within Qualigen’s family of RAS
oncogene protein-protein interaction inhibitor small molecules are
believed to inhibit or block the binding of mutated RAS genes’
proteins to their effector proteins, thereby leaving the proteins
from the mutated RAS unable to cause further harm. In theory, such
mechanism of action may be effective in the treatment of about one
quarter of all cancers, including certain forms of pancreatic,
colorectal, and lung cancers. Our investigational QN-247 compound
inhibits nucleolin, a key multi-functional regulatory protein that
is overexpressed in cancer cells; QN-247 may thereby be able to
inhibit the cells’ proliferation. QN-247 has shown promise in
preclinical studies for the treatment of acute myeloid leukemia
(AML). In addition to its oncology drug pipeline, Qualigen has an
established diagnostics business which manufactures and distributes
proprietary and highly accurate rapid blood testing systems to
physician offices and small hospitals for the management of
prostate cancer and other diseases and health conditions.
For more information about Qualigen
Therapeutics, Inc., please visit www.qualigeninc.com.
Contact:
Jules AbrahamJQA Partners,
Inc.917-885-7378jabraham@jqapartners.com
Source: Qualigen Therapeutics, Inc.
- Qualigen Therapeutics, Inc.
Grafico Azioni Qualigen Therapeutics (NASDAQ:QLGN)
Storico
Da Ago 2024 a Set 2024
Grafico Azioni Qualigen Therapeutics (NASDAQ:QLGN)
Storico
Da Set 2023 a Set 2024